June 12, 2008

Long on Osiris

Zacks has a buy on small cap Osiris and gives the company a $20 price target. This company makes drugs from human stems cells. In a partnership with Genzyme, they were recently awarded a $225 million contract from the Department of Defense.

Another article on the company was found at Seeking Alpha.

No comments: